Press Release: Novartis to Launch -2-

Improvements in the Signs and Symptoms in Psoriatic Arthritis: Final

5--Year Efficacy and Safety Results from a Phase 3 Trial". ACR/ARHP 2020

Annual Meeting Abstract. Presented in ACR Open Rheumatology (2020);

CONCL--00511 (Secukinumab Provides Sustained Improvements in the Signs

and Symptoms of Psoriatic Arthritis: Final 5-year Results from the Phase

3 FUTURE 1 Study - PubMed https://pubmed.ncbi.nlm.nih.gov/31943974/ )

10. McInnes IB, Mease PJ, Kivitz AJ, Nash P, Rahman P, Rech J, Conaghan PG,

Kirkham B, Navarra S, Belsare AD, Delicha EM, Pricop L, Mpofu S; FUTURE 2

Study Group. "Long--term efficacy and safety of secukinumab in patients

with psoriatic arthritis: 5--year (end--of--study) results from the phase

III FUTURE 2 study." Lancet Rheumatology. 2020; 2(4): e227--e235.

(Long-term efficacy and safety of secukinumab in patients with psoriatic

arthritis: 5-year (end-of-study) results from the phase 3 FUTURE 2 study

https://eprints.whiterose.ac.uk/id/eprint/156560/8/clean%20AAM.pdf )

11. Bissonnette R, Luger T, Thaçi D, Toth D, Lacombe A, Xia S, Mazur R,

Patekar M, Charef P, Milutinovic M, Leonardi C, Mrowietz U.Secukinumab

demonstrates high sustained efficacy and a favourable safety profile in

patients with moderate-to-severe psoriasis through 5 years of treatment

(SCULPTURE Extension Study). J Eur Acad Dermatol Venereol. 2018

Sep;32(9):1507--1514. (Secukinumab demonstrates high sustained efficacy

and a favourable safety profile in patients with moderate-to-severe

psoriasis through 5 years of treatment (SCULPTURE Extension Study) -

PubMed https://pubmed.ncbi.nlm.nih.gov/29444376/ )

# # #

Novartis Media Relations

E-mail: media.relations@novartis.com

Novartis Investor Relations

Central investor relations line:

+41 61 324 7944

E-mail: investor.relations@novartis.com

(END) Dow Jones Newswires

September 29, 2025 08:15 ET (12:15 GMT)